Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03163342 · ClinicalTrials.gov registry record · Phase 4
Immune Response Following Seasonal Influenza Vaccination
A Phase 4 study of Influenza, sponsored by Altimmune.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03163342 is a Phase 4 study of Influenza that has completed, run by Altimmune. The registered enrollment target is 20 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03163342, a Phase 4 study of Influenza, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent influenza vaccine.
Conditions Studied
Interventions
- BIOLOGICAL Licensed seasonal influenza vaccine
Study Locations (1)
Maryland
- Optimal Health Research - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03163342
The ClinicalTrials.gov registry entry for NCT03163342 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Licensed seasonal influenza vaccine is the first listed.
NCT03163342 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03163342 about?
NCT03163342 is a clinical study titled "Immune Response Following Seasonal Influenza Vaccination". This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent influenza vaccine.
What is the current status of trial NCT03163342?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2017-05-08. Estimated completion is 2018-06-15.
What conditions does trial NCT03163342 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT03163342?
The interventions under investigation include: Licensed seasonal influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03163342?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03163342 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.